Efficacy of tumor necrosis factor α blockade in primary central nervous system vasculitis resistant to immunosuppressive treatment

Arthritis Care and Research

Volumn 59, Issue 2, 2008, Pages 291-296

  Salvarani, Carlo ^a   Brown Jr , Robert D ^a,b   Calamia, Kenneth T ^b,c   Huston III, John ^a   Meschia, James F ^b,c   Giannini, Caterina ^a   Miller, Dylan V ^a   Hunder, Gene G ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; ETANERCEPT; INFLIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ANAMNESIS; ARTICLE; BRAIN VASCULITIS; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CONFUSION; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; SYMPTOM; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOPSY; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS, CENTRAL NERVOUS SYSTEM;

EID: 39449138985     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23337     Document Type: Article

References (15)

1. Calabrese LH, Duna GF, Lie JT. Vasculitis in the central nervous system [review]. Arthritis Rheum 1997;40:1189-201.
2. Moore PM. Diagnosis and management of isolated angiitis of the central nervous system. Neurology 1989;39:167-73.
3. Salvarani C, Brown RD Jr, Calamia KT, Christianson TJ, Weigand SD, Miller DV, et al. Primary central nervous system vasculitis; analysis of 101 patients. Ann Neurol 2007;62:442-51.
4. Hajj-Ali RA, Furlan A, Abou-Chebel A, Calabrese LH. Benign angiopathy of the central nervous system: cohort of 16 patients with clinical course and long-term followup. Arthritis Rheum 2002;47:662-9.
5. Salvarani C, Brown RD Jr, Calamia KT, Christianson TJ, Huston J III, Meschia JF, et al. Primary central nervous system vasculitis with prominent leptonieningeal enhancement: a subset with a benign outcome. Arthritis Rheum 2008;58:595-603.
6. Pipitone N, Olivieri I, Cantini F, Triolo G, Salvarani C. New approaches in the treatment of Adamantiades-Behçet's disease. Curr Opin Rheumatol 2006;18:3-9.
7. Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004;50:2296-304.
8. Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases [letter]. Arthritis Rheum 2001;44:2933-5.
9. Feldmann M, Pusey CD. Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases. J Am Soc Nephrol 2006;17:1243-52.
10. Lowder CY, Galor A, Perez VL. Differential effectiveness of etanercept and infliximab in ocular inflammation [abstract]. Invest Ophthamol Vis Sci 2005;46:2829. URL: http://abstracts.iovs.org/cgi/content/abstract/46/5/2829? maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&author1= perez%2C+vl&searchid=1&FIRSTINDEX=10&resourcetype HWCIT.
11. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-61.
12. Licata G, Pinto A, Tuttolomondo A, Banco A, Ciccia F, Ferrante A, et al. Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome [letter]. Ann Rhenm Dis 2003;62:280-1.
13. Ribi C, Sztajzel R, Delavelle J, Chizzolini C. Efficacy of TNF α blockade in cyclophosphamide resistant neuro-Behçet disease. J Neurol Neurosurg Psychiatry 2005;76:1733-5.
14. Sarwar H, McGrath H Jr, Espinoza LR. Successful treatment of long-standing neuro-Behçet's disease with infliximab. J Rheumatol 2005;32:181-3.
15. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005;34:819-36.